# Long-term outcomes of early initiated antiretroviral therapy in sub-Saharan children: a Cameroonian cohort study (ANRS-12140 Pediacam study, 2008–2013, Cameroon)

Francis Ateba Ndongo, Mathurin Cyrille Tejiokem, Calixte Ida Penda, Suzie Tetang Ndiang, Jean-Audrey Ndongo, Georgette Guemkam, Casimir Ledoux Sofeu, Paul Alain Tagnouokam-Ngoupo, Anfumbom Kfutwah, Philippe Msellati, et al.

► To cite this version:

Francis Ateba Ndongo, Mathurin Cyrille Tejiokem, Calixte Ida Penda, Suzie Tetang Ndiang, Jean-Audrey Ndongo, et al.. Long-term outcomes of early initiated antiretroviral therapy in sub-Saharan children: a Cameroonian cohort study (ANRS-12140 Pediacam study, 2008–2013, Cameroon). BMC Pediatrics, 2021, 21 (1), 10.1186/s12887-021-02664-6. doi:10.1186/s12887-021-02664-6

HAL Id: hal-03239267

https://u-paris.hal.science/hal-03239267

Submitted on 27 May 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
RESEARCH ARTICLE

Open Access

<figure><img src="image_2.png" /></figure>

Check for
updates

# Long-term outcomes of early initiated antiretroviral therapy in sub-Saharan children: a Cameroonian cohort study (ANRS-12140 Pediacam study, 2008–2013, Cameroon)

Francis Ateba Ndongo¹*, Mathurin Cyrille Tejiokem², Calixte Ida Penda³, Suzie Tetang Ndiang⁴, Jean-Audrey Ndongo⁵, Georgette Guemkam⁵, Casimir Ledoux Sofeu⁶, Paul Alain Tagnouokam-ngoupo⁷, Anfumbom Kfutwah⁷, Philippe Msellati⁸, Albert Faye⁹ and Josiane Warszawski¹⁰

**Abstract**

**Background:** In most studies, the virological response is assessed during the first two years of antiretroviral treatment initiated in HIV-infected infants. However, early initiation of antiretroviral therapy exposes infants to very long-lasting treatment. Moreover, maintaining viral suppression in children is difficult. We aimed to assess the virologic response and mortality in HIV-infected children after five years of early initiated antiretroviral treatment (ART) and identify factors associated with virologic success in Cameroon.

**Methods:** In the ANRS-12140 Pediacam cohort study, 2008–2013, Cameroon, we included all the 149 children who were still alive after two years of early ART. Virologic response was assessed after 5 years of treatment. The probability of maintaining virologic success between two and five years of ART was estimated using Kaplan-Meier curve. The immune status and mortality were also studied at five years after ART initiation. Factors associated with a viral load < 400 copies/mL in children still alive at five years of ART were studied using logistic regressions.

**Results:** The viral load after five years of early ART was suppressed in 66.8% (60.1–73.5) of the 144 children still alive and in care. Among the children with viral suppression after two years of ART, the probability of maintaining viral suppression after five years of ART was 64.0% (54.0–74.0). The only factor associated with viral suppression after five years of ART was achievement of confirmed virological success within the first two years of ART (OR = 2.7 (1.1–6.8); *p* = 0.033).

(Continued on next page)

<footnote>* Correspondence: atebfranc@gmail.com
¹Université Paris-Sud, Centre Mère et Enfant de la Fondation Chantal Biya, Francis, POB 1936, Yaounde, Cameroon
Full list of author information is available at the end of the article</footnote>
(Continued from previous page)

**Conclusions:** The probability of maintaining viral suppression between two and five years of early initiated ART which was quite low highlights the difficulty of parents to administer drugs daily to their children in sub-Saharan Africa. It also stressed the importance of initial viral suppression for achieving and maintaining virologic success in the long-term. Further studies should focus on identifying strategies that would enhance better retention in care and improved adherence to treatment within the first two years of ART early initiated in Sub-Saharan HIV-infected children.

**Keywords:** HIV-infected children, Early initiated antiretroviral treatment, Long-term outcomes

## Background

Over the last years, the beneficial effects of antiretroviral therapy (ART) have been reported among HIV-infected children [1–4]. Early initiation of ART in infants and young children has been proven to be associated with reduced morbidity and mortality [5–13]. Based on such evidence, ART treatment guidelines of the World Health Organization (WHO) and various countries have been updated to recommend early initiation of ART in HIV-infected infants [14–17], leading to an increase in child enrolment in sub-Saharan African pediatric ART programs [18–20].

In most studies, the virologic response is assessed during the first two years following ART initiation of HIV-infected infants [7–10, 12, 21–28]. Early initiation of ART in vertically HIV-infected children exposes them to a very long-lasting treatment relative to that of adults. Maintaining viral suppression in children is very difficult [8, 29, 30]. Pediatric ART options are limited in Sub-Saharan Africa due to low availability of pediatric formulations [16, 22, 31, 32]. Thus long-term success of early infant ART in Sub-Saharan Africa depends on the efficacy of first-line regimens [33, 34]. There is a need to study longer-term efficacy of early initiated ART in HIV-infected children.

In the ANRS-12140 Pediacam cohort study, Cameroonian HIV-infected children were initiated on ART at a median age of four months [35, 36]. We aimed to determine the virologic response and mortality after five years of antiretroviral treatment initiated during the first year of life based on data from this cohort study and identify factors associated with virologic success in a sub-Saharan country (Cameroon).

## Methods

### The ANRS-12140 Pediacam study

ANRS-12140 Pediacam is a prospective cohort study of HIV-infected children included between November 2007 and October 2011 from three referral hospitals in Cameroon: the “Centre Mère et Enfant de la Fondation Chantal Biya” (CME-FCB) and “Centre Hospitalier d’Es-sos” (CHE), both in Yaounde, and the “Hôpital Laquintinie de Douala” (HLD) in Douala. Pediacam comprised

two phases and has been described previously [35, 37]. Briefly, during the first phase, infants born to HIV-infected mothers and those born to HIV-uninfected mothers were matched according to gender and site of recruitment during the first week of life and followed until the fourteenth week. HIV-exposed infants were tested for HIV using Polymerase Chain Reaction (PCR) test at six weeks of age, according to the Cameroonian guidelines at the time of the study. Results of HIV test were available at 10 weeks with retesting for HIV-positive diagnoses. HIV-negative breastfed infants were retested six weeks after weaning. All HIV-infected infants and subsamples of uninfected HIV-exposed and HIV-unexposed infants were eligible for the second phase of follow-up, planned to continue until five years of age. During the above inclusion period, direct inclusion into the phase 2 follow-up was proposed to the mothers of HIV-infected infants identified and diagnosed after the first week but before seven months of life. Overall, 210 HIV-infected infants were included in this second phase. Antitretroviral therapy (ART) was systematically proposed as soon as the HIV status was confirmed, according to the Cameroonian guidelines at the time of the study: zidovudine (or abacavir or stavudine) + lamivudine, for all infants, combined with ritonavir-boosted lopinavir or nevirapine, depending on the previous history of nevirapine used for prevention of mother-to-child transmission (PMTCT). Viral load of HIV was measured by RT PCR (Biocentric, Bandol, France) using plasma specimen, with 300 copies/mL as lower limit of quantification from 2007 to 2011. Thereafter, new devices for measuring viral load were acquired with the threshold of 60 copies/mL as lower limit of quantification. Data concerning biological and clinical parameters were collected at inclusion and every three months after ART initiation until the age of two years and every six months thereafter. At the same time-points, a standardized questionnaire was administered to caregivers to collect data on family living conditions and adherence to ART. Children whose HIV viral load remained high (≥1000 copies/mL) for at least three consecutive medical visits were selected for HIV genotypic resistance test to ARVs performed with 1 mL of plasma
using the French ANRS (French National Agency for Research on AIDS and Viral Hepatitis) protocol [38]. The targeted regions were Protease and Reverse transcriptase of the HIV polymerase gene. The exams and transport fees were paid by the Pediacam project.

## Study population

We considered for this analysis the HIV-infected children included in phase 2 of the Pediacam study who were alive at two years of ART initiated no later than the age of one year (Fig. 1). Data were analyzed from the second to fifth year of ART.

## Endpoints

The main outcome variable for this study was virologic success (VS), defined on the one hand as the achievement of viral load < 400 copies/mL at least once during the period from two to five years after ART initiation, and one the other as the achievement of viral load < 400 copies/mL after five years of ART initiation. This threshold had also been reported in previous studies [9, 24, 39–41]. We also studied mortality and the immune status, defined by the percentage of CD4 lymphocytes, at five years after ART initiation.

Virologic, immunological, and clinical data were analyzed during the visits scheduled every six months from 24 months after ART initiation: month 24 (M24), month 30 (M30), month 36 (M36), month 42 (M42), month 48 (M48), month 54 (M54), and month 60 (M60). A window of three months before and after these time points was accepted for data collection. The monitoring values used were the nearest measurements within these ±3-month intervals. The children still alive who did not attend the scheduled visit were classified as virologic failure with respect to the corresponding visit.

## Exposure variables

We mainly considered characteristics at M24 to identify factors associated with VS at M60: calendar period, ART regimen, site of ART delivery, age and clinical presentation of the child, attainment of confirmed VS (at least two consecutive viral loads (VL) < 1000 copies/mL) achievement of confirmed virological success (at least two consecutive viral loads < 1000 copies/mL) at least once within the first two years after ART initiation) [42], virological status at M24 (viral load < or ≥ 1000 copies/mL), and immunological status (percentage of CD4 lymphocytes). We also considered variables related to living

<figure><img src="image_3.png" /></figure>
conditions at M24: people living in the household, access to running water, access to electricity, and availability of a functional refrigerator at home. Finally, we considered the reporting of caregiver adherence (recall of missed doses in the past three days) collected at M60. Children were classified as non-adherent if at least one dose was missed during the past three days [18, 36].

## Statistical analysis

The study population was initially divided into two groups by distinguishing their virological status at two years of ART: 1) children who had a viral load < 400 copies/mL at M24 (Group 1) and 2) children who had a viral load ≥400 copies/mL or whose viral load had not been measured at M24 (15 children of whom the last viral load measured was ≥400 copies/mL at M12) (Group 2). The characteristics at two years of treatment according to a viral load below or above 400 copies/mL were compared by grouping together the children whose viral load was ≥400 copies/mL or not measured.

The probability of maintaining VS from M24 to M60 for group 1 was estimated using the Kaplan-Meier model. The probability of achieving VS for group 2 was estimated using a competing risk regression curve (with death as the competing event).

The association of exposure variables with viral load < 400 copies/mL (versus a viral load ≥400 copies/mL) at M60 for children who were still alive was assessed in univariate and multivariate analysis using logistic regression. The site of ART delivery, virological status at M24, ART regimen at M24, and reporting of caregiver adherence (recall of missed doses in the past three days) at M60 were included in all multivariate models (a priori risk factors). Other exposure variables, with $p \le 0.20$ in univariate analysis, were also included in the initial multivariate model. The final model was built using backwards elimination, comprising a priori risk factors and other exposure variables with $p \le 0.20$. All statistical analyses were performed using STATA® 13.0 (Stata Corp, College Station, TX).

## Results

### Study population

Among the 210 HIV-infected children included in phase 2 of the Pediacam study, 149 (71.1%) who initiated ART no later than the age of one year were alive at two years and considered for this analysis (Fig. 1). Of the 61 HIV-infected children who were not included in this study, 12 (19.7%) where deceased before ART, 5 (8.2%) were lost to follow-up or relocated before ART, 3 (4.9%) were placed on ART after age 12 months, 38 (62.3%) deceased within the first two years of ART and 3 (4.9%) were lost to follow-up before 2 years of ART initiation. Among the 149 children (82 boys) followed-up and still alive at two years

after ART initiation, with ART started during the first year of life, almost three quarters (73.9%) were enrolled in the two Yaounde sites (Table 1). The median age of the children at two years after ART initiation (origin of time for this analysis) was 28.5 months (IQR: 27.1–30.0). Most (75.6%) were living with their mothers (with or without their fathers) in households of which 39.4% had running water, 93.6% electricity, and 51.1% a functional refrigerator. The ART regimen two years after treatment initiation was comprised of lopinavir boosted with ritonavir (74.5%) or nevirapine (25.5%), with a median percentage of CD4 lymphocytes of 33.6% (24.1–40.4).

At two years after ART initiation, most of the children (77.2%) had achieved a confirmed VS at least once [42] and a viral load measurement was available for 134, of whom 67.2% were < 400 copies/mL («controlled viral load»). Among the 15 other children, the last available viral load was ≥400 copies/mL for 12 (80.0%).

The children with VS at two years of treatment were more often girls than boys (62.2% versus 37.8%, $p = 0.017$) and almost all (96.7%) had achieved confirmed virological success (CVS) at least once before two years of treatment, whereas this was true for only 45.5% of the other children ($p < 0.001$).

### Mortality and retention in care between two and five years after ART initiation

Among the 149 children alive at two years of treatment and included in this study, a viral load measurement was available at M60 for 121 (81.2%) and 23 (15.4%) did not have viral load measurements at five years of ART whilst they were still alive (Table 2). Of these, 12 (8.1%) did not attend any clinical visit since the time period before M24. Five (3.4%) deaths were recorded M24 and M60, corresponding to a death rate of 3.0% (95%CI: 0.2–5.8%) estimated using the Kaplan Meier method. Among them, 2 (40.0%) occurred in children with a viral load ≥400 copies/mL and 3 (60.0%) in children whose viral load was unavailable at two years of treatment, whereas there were no deaths among children with VS at two years of treatment.

### Immunological status at five years of antiretroviral treatment

Among the children included in this study, almost three quarters (77.2%) had a high CD4 percentage level (≥25%) at 5 years of ART (Table 2).

### Virologic control at five years of antiretroviral treatment

Virologic control at five years of ART was estimated at 66.8% (60.1–73.5) among the 144 children still alive after five years of treatment. The viral load measurement was not available in 23 (16.0%) of them at that deadline (Table 2). Among the children who were virologically
<table><caption>**Table 1** Baseline characteristics of HIV-infected children alive at 24 months after early antiretroviral treatment initiation (ANRS-Pediacam Study, 2008–2013, Cameroon) (N = 149)</caption><thead><tr><th></th><th>N</th><th>% (n) or median (IQR)</th></tr></thead><tbody><tr><td><strong>Male</strong></td><td>149</td><td>55.0 (82)</td></tr><tr><td><strong>Site of ART delivery</strong></td><td>149</td><td></td></tr><tr><td>CME/FCB</td><td></td><td>51.7 (77)</td></tr><tr><td>HLD</td><td></td><td>22.2 (33)</td></tr><tr><td>CHE</td><td></td><td>26.1 (39)</td></tr><tr><td><strong>At 24 months after ART initiation (Study start)</strong></td><td></td><td></td></tr><tr><td><strong>Age at 2 years after ART initiation</strong></td><td>149</td><td></td></tr><tr><td>&lt; 28 months (treatment initiated before age 4 months of age)</td><td></td><td>50.3 (75)</td></tr><tr><td>[28–30[months (treatment initiated between age 4 and 6 months)</td><td></td><td>30.2 (45)</td></tr><tr><td>≥ 30 months (treatment initiated from 6 months of age)</td><td></td><td>19.5 (29)</td></tr><tr><td>Median (IQR)</td><td></td><td>28.5 (27.1–30.0)</td></tr><tr><td><strong>Time period</strong></td><td>149</td><td></td></tr><tr><td>2010–2011</td><td></td><td>65.1 (97)</td></tr><tr><td>2012–2013</td><td></td><td>34.9 (52)</td></tr><tr><td><strong>ART regimen</strong></td><td>149</td><td></td></tr><tr><td>Lopinavir-based</td><td></td><td>74.5 (111)</td></tr><tr><td>Nevirapine-based</td><td></td><td>25.5 (38)</td></tr><tr><td><strong>Children living with</strong></td><td>131</td><td></td></tr><tr><td>Both parents</td><td></td><td>38.9 (51)</td></tr><tr><td>Mother only</td><td></td><td>36.7 (48)</td></tr><tr><td>Father only</td><td></td><td>5.3 (7)</td></tr><tr><td>Other relatives</td><td></td><td>19.1 (25)</td></tr><tr><td><strong>Family size ≤ 5 people</strong></td><td>94</td><td>47.9 (45)</td></tr><tr><td><strong>Access at child's home to</strong></td><td>94</td><td></td></tr><tr><td>Refrigerator</td><td></td><td>51.1 (48)</td></tr><tr><td>Running water</td><td></td><td>39.4 (37)</td></tr><tr><td>Electricity</td><td></td><td>93.6 (88)</td></tr><tr><td><strong>CD4 percentage at 2 years after ART initiation</strong></td><td>131</td><td></td></tr><tr><td>&lt; 15</td><td></td><td>6.1 (8)</td></tr><tr><td>[15–20[</td><td></td><td>6.1 (8)</td></tr><tr><td>20–25[</td><td></td><td>14.5 (19)</td></tr><tr><td>≥ 25</td><td></td><td>73.3 (96)</td></tr><tr><td>Not measured</td><td></td><td>13</td></tr><tr><td>Median (IQR), N = 131</td><td></td><td>33.6 (24.5–41.6)</td></tr><tr><td><strong>Virological status</strong></td><td></td><td></td></tr><tr><td><strong>Achievement of confirmed virological success (CVS) within the first two years of ART</strong></td><td>149</td><td></td></tr><tr><td>Yes (≥2 VL &lt; 1000 copies/mL for two consecutive measurements)</td><td></td><td>77.2 (115)</td></tr><tr><td>No</td><td></td><td>22.8 (34)</td></tr><tr><td><strong>Virological status at 2 years (±3 months) after ART initiation</strong></td><td>134</td><td></td></tr><tr><td>VL &lt; 400 copies/mL</td><td></td><td>67.2 (90)</td></tr><tr><td>VL ≥ 400 copies/mL</td><td></td><td>32.8 (44)</td></tr><tr><td>VL not measured</td><td></td><td>15</td></tr><tr><td><strong>Last viral load if not available at 2 years ± 3 months after ART initiation</strong></td><td>15</td><td></td></tr><tr><td>VL &lt; 400 copies/mL</td><td></td><td>12</td></tr><tr><td>VL ≥ 400 copies/mL</td><td></td><td>3</td></tr></tbody></table>

N: total number of subjects; n: number of subjects in the category; ART antiretroviral therapy; CME/FCB Centre Mère et Enfant de la Fondation Chantal Biya; HLD Hôpital Laquintinie de Douala; CHE Centre Hospitalier d'Essos; IQR interquartile range; VL viral load
<table><caption>**Table 2** Mortality and immuno-virological status at 5 years (+/-3 months) of children with antiretroviral treatment initiated within the first year of life (ANRS-Pediacam Study, 2008–2013, Cameroon) (N = 149)</caption><thead><tr><th rowspan="3"></th><th colspan="6">Viral load at 2 years (+/- 3 months) of antiretroviral treatment initiation</th></tr><tr><th colspan="2">All<br/>N = 149</th><th colspan="2">&lt; 400 copies/mL<br/>N = 90</th><th colspan="2">≥ 400 copies/mL<br/>N = 44</th><th colspan="2">Absence of viral load<br/>N = 15</th></tr><tr><th>N</th><th>%</th><th>N</th><th>%</th><th>N</th><th>%</th><th>N</th><th>%</th></tr></thead><tbody><tr><td colspan="9"><strong>Death between 2 and 5 years of ART initiation</strong></td></tr><tr><td>Yes</td><td>5</td><td>3.4</td><td>0</td><td>0.0</td><td>2</td><td>8.5</td><td>3</td><td>20.0</td></tr><tr><td>No</td><td>144</td><td>94.6</td><td>90</td><td>100.0</td><td>42</td><td>91.5</td><td>12</td><td>80.0</td></tr><tr><td colspan="9"><strong>Virological status at 5 years (+/-3 months) after ART initiation</strong></td></tr><tr><td>VL &lt; 400 copies/mL</td><td>99</td><td>66.4</td><td>68</td><td>75.6</td><td>28</td><td>63.6</td><td>3</td><td>20.0</td></tr><tr><td>VL ≥ 400 copies/mL</td><td>22</td><td>14.8</td><td>9</td><td>10.0</td><td>12</td><td>27.3</td><td>1</td><td>6.7</td></tr><tr><td>Absence of VL if not dead at M60</td><td>23</td><td>15.4</td><td>13</td><td>14.4</td><td>2</td><td>4.6</td><td>8</td><td>53.3</td></tr><tr><td colspan="9"><strong>Probability at 5 years (+/-3 months) after ART initiation, using Kaplan-Meier estimation method</strong></td></tr><tr><td>Of maintaining virological success (Group 1)</td><td>90</td><td>64.0</td><td>(30 events)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Of achieving at least once VL &lt; 400 copies/mL (Group 2)</td><td>44</td><td>76.0</td><td>(30 events)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="9"><strong>CD4 percentage at 5 years of ART initiation</strong></td></tr><tr><td>&lt; 15</td><td>1</td><td>0.7</td><td>0</td><td>0.0</td><td>1</td><td>2.3</td><td>0</td><td>0.0</td></tr><tr><td>[15–20]</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td></tr><tr><td>[20–25]</td><td>7</td><td>4.7</td><td>5</td><td>5.6</td><td>1</td><td>2.3</td><td>1</td><td>6.7</td></tr><tr><td>≥ 25</td><td>115</td><td>77.2</td><td>74</td><td>82.2</td><td>38</td><td>63.6</td><td>3</td><td>20.0</td></tr><tr><td>Not measured if not dead at M60</td><td>21</td><td>14.1</td><td>11</td><td>12.2</td><td>2</td><td>4.6</td><td>8</td><td>53.3</td></tr></tbody></table>

N: total number of subjects; n: number of subjects in the category; ART antiretroviral therapy; IQR interquartile range; VL viral load; M60 60 months of ART initiation; 95% CI: 95% confidence interval

controlled (viral load < 400 copies/mL) at two years of treatment, the probability of maintaining virologic control at five years, estimated using the Kaplan-Meier method, was 64.0% (54.0–74.0), (Table 2 and Fig. 2). Of those whose viral load was uncontrolled or unknown at two years of ART, the probability of achieving a viral load < 400 copies/mL between two and five years was 76.0% (63.0–89.0).

Genotypic resistance test of HIV to antiretroviral drugs was performed for a sample of 25 children whose viral load remained high (≥1000 copies/mL) for at least three consecutive medical visits during the study. Of these, 15 (60.0%) were boys and 18 (72.0%) have initiated lopinavir-based ART. The distribution of sex and type of ART in this sample was comparable to the study population. Among these children, 5 (20.0%) rebounded to viral load ≥1000 copies/mL during the study period for at least 3 consecutive visits before suppressing to viral load < 400 copies/mL no later than five years of ART. Overall, respectively 14 (56.0%), 9 (36.0%) and 2 (8.0%) of these children had no resistance, only lamivudine (3TC) resistance (not altering the effectiveness of current ART regimen) and resistance to non-3TC drugs (altering the effectiveness of current ART regimen). The resistance pattern did not differ by whether the child was suppressed or not at 5 years of ART, according to the Fisher exact test (p = 0.440).

## Factors associated with virological success at five years of antiretroviral treatment

In univariate analysis (Table 3), VS at five years of treatment (viral load < 400 copies/mL versus viral load ≥400 copies/mL or not measured) was associated with female gender (OR = 2.1 (1.0–4.4), p = 0.041) and achievement of confirmed virological success at least once within the first two years of ART (OR = 3.0 (1.3–6.9), p = 0.010). There was a non-significant association between VS at M60 and controlled viral load (VL < 400 copies/mL) at two years of ART initiation (OR = 2.2 (0.9–4.8), p = 0.061), being followed at “Centre Hospitalier d’Essos” versus “Centre Mère et Enfant de Yaoundé” and “Hôpital Laquintinie de Douala” (OR = 2.8 (1.0–7.6), p = 0.056) and absence of missed doses during the last three days before the M60 visit (OR = 2.8 (0.9–8.7), p = 0.076).

In multivariate analysis (Table 3), achievement of confirmed virological success at least once within the first two years of ART was associated with VS at five years of treatment (adjusted OR = 2.7 (1.1–6.8); p = 0.033). The trend between VS and absence of missed doses during the last three days before the M60 visit remained (adjusted OR = 2.7 (0.9–10.4), p = 0.075).

## Discussion

The proportion of VS among children still alive and followed-up at five years of treatment, initiated before
<figure><img src="image_4.png" /><figcaption>**Fig. 2** Kaplan-Meier curve: probability of maintaining a viral load < 400 copies/mL between 2 and 5 years after antiretroviral treatment initiation among the 90 children with a viral load < 400 copies/mL at 2 years after antiretroviral treatment initiation (ANRS-Pediacam Study, 2008–2013, Cameroon)</figcaption></figure>

the age of 12 months, was 66.8% (60.1–73.5), comparable to the results reported for Italian children who initiated ART early [43], and adult populations [44]. This result contrasts with a lower proportion of VS reported in a study conducted on children in Ivory Coast who initiated ART at a higher median age (36 months versus 4 months in our study) [45].

Among children alive at two years of treatment, 23 (15.4%) did not have viral load measurements at five years whilst they were still alive. Active telephone recalls of non-returning families made it possible to hear regularly from these children [46]. The low mortality beyond the first two years of antiretroviral treatment (3.3% (95%CI: 0.4–6.2)) is coherent with the results of other studies conducted in children and adults. Most deaths occurred during the first year of ART [9, 28, 44, 47–49]. The high mortality observed in the cohort before age 2 years of ART may reflect the rapid progression of the disease in infants enrolled in medical care after severe immunodeficiency had set in [42].

The probability of maintaining VS between two and five years of ART, estimated at 64.0% (54.0–74.0), highlights the difficulty of parents to administer drugs daily to their children [42]. The only factor independently associated with a controlled viral load (< 400 copies/mL) at five years of treatment was the existence of VS at two years of treatment, irrespective of living conditions. The association with VS at two years of ART may be related to factors that favor long-term family adherence to ART

or favorable immunological or virological factors in these children [50].

One of the strengths of our study was the use of data from a prospective cohort of children, with scheduled determinations of viral load at six-month intervals, making it possible to use survival models.

Some limitations of this study included the use of current missed doses self-reported by the child caregiver. It may not be a good stool for detecting virological success at 5 years of ART. It does not reflect the longitudinal adherence evolvement. It has been demonstrated previously that the negative predictive value of current missed dose in detecting virological success [36] was as satisfactory as cumulative missed doses (around 75%). In fact, virological response seems to be mostly influenced by adherence status within the last three months, especially when there is no drug resistance. The non-significant association between the absence of missed doses during the last three days before the M60 visit and virological success at this deadline would become significant if the study population size was larger. This hypothesis would confirm the difficulty of parents to administer daily medications to their children, given the difficulty in this study to maintain virologic suppression in children who had initiated ART early during infancy. We did not obtain exhaustive genotyping results for all the children in this study. The HIV-resistance patterns were similar, irrespective of virological status at five years of treatment, among the 25 children who were tested for
<table><caption>**Table 3** Factors associated with virological success (Viral load < 400 copies/mL versus > 400 copies/mL or not measured) in HIV-infected children at 5 years after early antiretroviral treatment initiation (ANRS-Pediacam Study, 2008–2013, Cameroon)</caption><thead><tr><th rowspan="2">Baseline characteristics at 2 years +/- 3 months after ART initiation</th><th colspan="5">Univariate analysis<br/>VL &lt; 400 cp/mL at 5 years +/- 3<br/>months after ART initiation</th><th colspan="3">Multivariate analysis<br/>(logistic regression)</th></tr><tr><th>N</th><th>n</th><th>%</th><th>Crude OR<br/>(95%CI)</th><th>p</th><th>Adjusted<br/>OR<br/>(95%CI)</th><th>p</th><th>N2</th></tr></thead><tbody><tr><td><strong>Gender</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>142</td></tr><tr><td>Male</td><td>65</td><td>39</td><td>60.0</td><td>1</td><td>0.041</td><td></td><td>0.122</td><td></td></tr><tr><td>Female</td><td>79</td><td>60</td><td>76.0</td><td>2.1 (1.0-4.4)</td><td></td><td>1.9 (0.9-<br/>4.2)</td><td></td><td></td></tr><tr><td><strong>Site of ART delivery</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CME/FCB</td><td>74</td><td>47</td><td>63.5</td><td>1</td><td>0.056</td><td>1</td><td>0.102</td><td></td></tr><tr><td>HLD</td><td>30</td><td>19</td><td>63.3</td><td>0.8 (0.3-18)</td><td></td><td>0.7 (0.3-<br/>1.8)</td><td></td><td></td></tr><tr><td>CHE</td><td>40</td><td>33</td><td>82.5</td><td>2.8 (1.0-7.6)</td><td></td><td>2.4 (0.8-<br/>7.2)</td><td></td><td></td></tr><tr><td><strong>Age</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&lt; 28 months (treatment initiated before age of 4 months)</td><td>72</td><td>50</td><td>69.4</td><td>1</td><td>0.855</td><td></td><td></td><td></td></tr><tr><td>≥ 28 months (treatment initiated from age of 4 months)</td><td>72</td><td>49</td><td>68.1</td><td>0.9 (0.5-1.9)</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Calendar period</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2010-2011</td><td>91</td><td>63</td><td>69.2</td><td>1</td><td>0.923</td><td>1</td><td>0.206</td><td></td></tr><tr><td>2012-2013</td><td>53</td><td>36</td><td>67.9</td><td>1.0 (0.5-2.0)</td><td></td><td>1.8 (0.7-<br/>4.4)</td><td></td><td></td></tr><tr><td><strong>Virological response within the first two years of ART</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Absence of confirmed virological success</td><td>29</td><td>15</td><td>51.7</td><td>1</td><td>0.010</td><td>1</td><td>0.033</td><td></td></tr><tr><td>Achievement of confirmed virological success at least once (= 2 VL &lt; 1000 copies/<br/>mL for two consecutive measurements)</td><td>115</td><td>84</td><td>73.0</td><td>3.0 (1.3-6.9)</td><td></td><td>2.7 (1.1-<br/>6.8)</td><td></td><td></td></tr><tr><td><strong>Virological status</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>VL ≥ 400 copies/mL or not measured</td><td>54</td><td>29</td><td>53.7</td><td>1</td><td>0.061</td><td></td><td></td><td></td></tr><tr><td>VL &lt; 400 copies/mL</td><td>90</td><td>70</td><td>77.7</td><td>2.2 (0.9-4.8)</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Children living with<sup>(1)</sup></strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mother or father</td><td>96</td><td>77</td><td>80.2</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Other relatives</td><td>23</td><td>23</td><td>100.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Availability of refrigerator in the household</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>40</td><td>34</td><td>85.0</td><td>1</td><td>0.939</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>44</td><td>36</td><td>81.8</td><td>1.0 (0.4-2.6)</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Access to electricity at home<sup>(1)</sup></strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>5</td><td>3</td><td>60.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>79</td><td>67</td><td>84.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Access to water at home<sup>(1)</sup></strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>52</td><td>42</td><td>80.9</td><td>1</td><td>0.876</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>32</td><td>28</td><td>87.5</td><td>1.0 (0.4-3.0)</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>History of hospitalization, diarrhea, infectious disease, or convulsions within the last 3 months before the M60 visit</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>75</td><td>59</td><td>78.7</td><td>1</td><td>0.975</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>45</td><td>37</td><td>82.2</td><td>1.0 (0.5-2.3)</td><td></td><td></td><td></td><td></td></tr></tbody></table>
<table><caption>**Table 3** Factors associated with virological success (Viral load < 400 copies/mL versus > 400 copies/mL or not measured) in HIV-infected children at 5 years after early antiretroviral treatment initiation (ANRS-Pediacam Study, 2008–2013, Cameroon) (Continued)</caption><thead><tr><th rowspan="2">Baseline characteristics at 2 years +/- 3 months after ART initiation</th><th colspan="5">Univariate analysis<br/>VL < 400 cp/mL at 5 years +/- 3<br/>months after ART initiation</th><th colspan="3">Multivariate analysis<br/>(logistic regression)</th></tr><tr><th>N</th><th>n</th><th>%</th><th>Crude OR<br/>(95%CI)</th><th>p</th><th>Adjusted<br/>OR<br/>(95%CI)</th><th>p</th><th>N2</th></tr></thead><tbody><tr><td><strong>CD4 percentage<sup>(2)</sup></strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>142</td></tr><tr><td>&lt; 25%</td><td>30</td><td>29</td><td>96.2</td><td>1</td><td>0.221</td><td></td><td></td><td></td></tr><tr><td>≥ 25%</td><td>89</td><td>70</td><td>78.7</td><td>0.5 (0.2–1.5)</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>ART regimen</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Lopinavir-based</td><td>106</td><td>77</td><td>72.6</td><td>1</td><td>0.117</td><td>1</td><td>0.155</td><td></td></tr><tr><td>Nevirapine-based</td><td>38</td><td>22</td><td>57.9</td><td>0.5 (0.2–1.2)</td><td></td><td>0.5 (0.2–<br/>1.3)</td><td></td><td></td></tr><tr><td><strong>Number of missed doses within the last 3 days before M60 visit</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≥ 1 missed dose</td><td>95</td><td>77</td><td>81.1</td><td>1</td><td>0.076</td><td>1</td><td>0.075</td><td></td></tr><tr><td>No missed dose</td><td>30</td><td>22</td><td>73.3</td><td>2.8 (0.9–8.7)</td><td></td><td>2.7 (0.9–<br/>10.4)</td><td></td><td></td></tr></tbody></table>

VL viral load; ART antiretroviral therapy; OR odds ratio; 95%CI: 95% confidence interval; N total number of subjects at 5 years after treatment initiation; n: number of subjects with virological success at 5 years after treatment initiation; p: statistical test; N2 total number of subjects in final multivariate model; VL: viral load; (1): Variable excluded from the univariate and multivariate analyses because of unbalanced sizes of categories; (2): Variables excluded from the multivariate analysis because of collinearity with virological status at 2 years after treatment initiation

genotyping. It is not possible to draw conclusions on the effect of HIV resistance mutations on the virological response at five years of ART early initiated during infancy because the study was not sufficiently powered to address this issue.

## Conclusions

This study reported difficulty in maintaining virologic success in sub-Saharan HIV-infected children between two and five years of early initiated ART. It also highlighted the importance of initial viral suppression for achieving and maintaining virologic success in the long-term. Further studies should focus on identifying strategies that would enhance better retention in care and improved adherence to treatment within the first two years of ART early initiated in Sub-Saharan HIV-infected children.

### Abbreviations

ART: Antiretroviral therapy; HIV: Human Immunodeficiency Virus; ANRS: French National Agency for Research on AIDS and Viral Hepatitis; VS: Virologic success; M24: 24 months after ART initiation; M30: 30 months after ART initiation; M36: 36 months after ART initiation; M42: 42 months after ART initiation; M48: 48 months after ART initiation; M54: 54 months after ART initiation; M60: 60 months after ART initiation; 95%CI: 95% confidence interval

### Acknowledgements

We are grateful to all the members of the Pediacam study group for their commitment to the success of this study. We thank the parents who agreed the inclusion of their children in this study.

### Authors' contributions

FAN participated in the study design and conception, the recruitment and follow up of HIV-infected infants, the data analysis and the manuscript writing. MCT participated in the study design and conception, the data analysis, the manuscript writing and the study coordination. CIP participated in the study design and conception, the recruitment and follow up of HIV-infected infants and the manuscript writing. STN, JAN and GG participated in the recruitment and follow up of HIV-infected infants and the manuscript writing. AK participated in the study design and conception, manuscript writing and the study coordination. CLS participated in data analysis and the manuscript writing. AF and JW participated in the study design and conception, the data analysis, the manuscript writing and the study coordination. PAT-N and PM participated in the data analysis and the manuscript writing. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

### Funding

No funding was provided for this study.

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Declarations

#### Ethics approval and consent to participate

The ANRS-Pediacam study was granted ethical approval in Cameroon by the National Ethics Committee and in France by the Biomedical Research Committee of the Pasteur Institute of Paris. Parents signed written informed consent for participation in the study.

#### Consent for publication

Not applicable.

#### Competing interests

The authors have no conflicts of interest relevant to this article to disclose.
Author details

¹Université Paris-Sud, Centre Mère et Enfant de la Fondation Chantal Biya, Francis, POB 1936, Yaounde, Cameroon. ²Centre Pasteur du Cameroun, Service d'Epidémiologie et de Santé Publique, Yaounde, Cameroon. ³MPH, PH-PU, Université Douala; Hôpital Laquintinie, Douala, Cameroon. ⁴Centre Hospitalier d'Essos, Yaounde, Cameroon. ⁵Centre Mère et Enfant de la Fondation Chantal Biya, Yaounde, Cameroon. ⁶Université Yaoundé I; Centre Pasteur du Cameroun, Service d'Epidémiologie et de Santé Publique, Yaounde, Cameroon. ⁷Centre Pasteur du Cameroun, Service de Virologie, Yaounde, Cameroon. ⁸TransVIHMI, IRD, Montpellier, France. ⁹Université Paris Diderot, Sorbonne Paris Cité; Assistance Publique des Hôpitaux de Paris, Pédiatrie Générale, Hôpital Robert Debré, INSERM UMR 1123, ECEVE, Paris, France. ¹⁰Université Paris-Sud, Assistance Publique des Hôpitaux de Paris, CESP INSERM U1018, team 4 "HIV and STD", Hôpital Bicêtre, 94276 Le Kremlin-Bicêtre, France.

Received: 13 May 2020 Accepted: 12 April 2021

Published online: 21 April 2021

References

1. Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996–2006: planning for teenage and adult care. Clin Infect Dis Off Publ Infect Dis Soc Am. 2007;45(7):918–24.

2. Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, et al. Declines in Mortality Rates and Changes in Causes of Death in HIV-1-Infected Children during the HAART Era. J Acquir Immune Defic Syndr. 2010;53(1):86–94.

3. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA. 2000;284(2):190–7.

4. Janssens B, Raleigh B, Soeung S, Akao K, Te V, Gupta J, et al. Effectiveness of Highly Active Antiretroviral Therapy in HIV-Positive Children: Evaluation at 12 Months in a Routine Program in Cambodia. Pediatrics. 2007;120(5):e1134–40.

5. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233–44.

6. Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants: AIDS. mars. 2009;23(5):597–604.

7. Purchase SE, Van der Linden DJ, McKerrow NH. Feasibility and effectiveness of early initiation of combination antiretroviral therapy in HIV-infected infants in a government clinic of Kwazulu-Natal, South Africa. J Trop Pediatr. 2012;58(2):114–9.

8. Meyers TM, Yotebieng M, Kuhn L, Moultrie H. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. Pediatr Infect Dis J. 2011;30(11):974–9.

9. Tukei VJ, Murungi M, Asimwe AR, Migisha D, Maganda A, Bakeera-Kitaka S, et al. Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda. BMC Pediatr. 2013;13:42.

10. Sauvageot D, Schaefer M, Olson D, Pujades-Rodriguez M, O'Brien DP. Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children <5 years of age. Pediatrics. 2010;125(5):e1039–47.

11. Aboulker J-P, Babiker A, Chaix ML, Compagnucci A, Darbyshire J, Debré M, et al. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS Lond Engl. 2004;18(2):237–45.

12. Eley B, Davies M-A, Apolles P, Cowburn C, Buys H, Zampoli M, et al. Antiretroviral treatment for children. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. 2006;96(9 Pt 2):988–93.

13. Chiappini E, Galli L, Tovo P-A, Gabiano C, Gattinara GC, Guarino A, et al. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS. 2006; 20(2):207–15.

14. WHO. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Geneva: World Health Organization; 2006.

15. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach:

2010 Revision [Internet]. Geneva: World Health Organization; 2010. [cité 21 nov 2014]. (WHO guidelines approved by the guidelines review committee). Disponible sur: http://www.ncbi.nlm.nih.gov/books/NBK138576/

16. OMS | Lignes directrices unifiées sur l'utilisation des antirétroviraux pour le traitement et la prévention de l'infection à VIH [Internet]. [cité 9 mars 2016]. Disponible sur: http://www.who.int/hiv/pub/guidelines/avr2013/download/fr/

17. Doherty M, Ford N, Vitoria M, Weiler G, Hirnschall G. The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities. Curr Opin HIV AIDS. 2013;8(6):528–34.

18. Davies M-A, Boulle A, Fakir T, Nuttall J, Eley B. Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr. 2008;8:34.

19. WHO | Progress report 2011: Global HIV/AIDS response [Internet]. WHO. [cité 13 avr 2016]. Disponible sur: http://www.who.int/hiv/pub/progress_report2011/en/

20. Fact sheet 2015 | UNAIDS [Internet]. [cité 8 mars 2016]. Disponible sur: http://www.unaids.org/en/resources/campaigns/HowAIDScha ngedeverything/factsheet

21. Goetghebuer T, Le Chenadec J, Haelterman E, Galli L, Dollfus C, Thorne C, et al. Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation. Clin Infect Dis. 2012;54(6):878–81.

22. WHO | Scaling up priority HIV/AIDS interventions in the health sector [Internet]. WHO. [cité 10 déc 2015]. Disponible sur: http://www.who.int/hiv/pub/2010progressreport/report/en/

23. Porter M, Davies M-A, Mapani MK, Rabie H, Phiri S, Nuttall J, et al. Outcomes of Infants Starting Antiretroviral Therapy in Southern Africa, 2004–2012. J Acquir Immune Defic Syndr. 2015;69(5):593–601.

24. Duong T, Judd A, Collins IJ, Doerholt K, Lyall H, Foster C, et al. Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland. AIDS Lond Engl. 2014;28(16):2395–405.

25. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, et al. Response to combination antiretroviral therapy: variation by age. AIDS Lond Engl. 2008;22(12):1463–73.

26. Ndondoki C, Dicko F, Ahuatchi Coffie P, Kassi Eboua T, Koumavi Ekouevi D, Kouadio K, et al. Antiretroviral treatment response of HIV-infected children after prevention of mother-to-child transmission in West Africa. J Int AIDS Soc. 2014;17(1) [cité 29 avr 2016]. Disponible sur: http://www.jiasociety.org/index.php/jias/article/view/18737.

27. The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Response to early antiretroviral therapy in HIV-1 infected infants in Europe, 1996–2008. AIDS Lond Engl. 2011;25(18):2279–87.

28. Walker AS, Doerholt K, Sharland M, Gibb DM, Collaborative HIV. Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS Lond Engl. 2004;18(14):1915–24.

29. van Rossum AMC, Fraaij PLA, de Root R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002;2(2):93–102.

30. Fraaij PLA, Verweel G, van Rossum AMC, van Lochem EG, Schutten M, Weemaes CMR, et al. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2005;40(4):604–8.

31. American Academy of Pediatrics Committee on Pediatric AIDS, Section on International Child Health, Havens PL, Gibb DM. Increasing antiretroviral drug access for children with HIV infection. Pediatrics. 2007;119(4):838–45.

32. Church JD, Omer SB, Guay LA, Huang W, Lidstrom J, Musoke P, et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV-infected despite receiving single dose (SD) nevirapine (NVP) vs. SD NVP plus daily NVP up to 6-weeks of age to prevent HIV vertical transmission. J Infect Dis. 2008;198(7):1075–82.

33. Fitzgerald G, Penazzato M, Gibb D. Development of Antiretroviral Resistance in Children With HIV in Low- and Middle-Income Countries. J Infect Dis. 2013;207(suppl 2):S85–92.

34. Sigaloff KCE, Calis JCJ, Geelen SP, van Vugt M, de Wit TFR. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis. 2011;11(10):769–79.

35. Tejiokem MC, Warszawski J, Ateba Ndongo F, Tetang Ndiang S, Ndongo JA, Owona F, et al. Feasibility of routinely offering early combined antiretroviral
therapy to HIV-infected infants in a resource-limited country: the ANRS-PediaCAM study in Cameroon. Pediatr Infect Dis J. 2015;34(10):e248–53.

36. Ateba Ndongo F, Warszawski J, Texier G, Penda I, Tetang Ndiang S, Ndongo J-A, et al. Could caregiver reporting adherence help detect virological failure in Cameroonian early treated HIV-infected infants? BMC Pediatr. 2015;15(1):132.

37. Tejiokem MC, Faye A, Penda IC, Guemkam G, Ateba Ndongo F, Chewa G, et al. Feasibility of early infant diagnosis of HIV in resource-limited settings: the ANRS 12140-PEDIACAM study in Cameroon. PLoS One. 2011;6(7):e21840.

38. HIV French Resistance - HIV-1 genotypic drug resistance interpretation's algorithms [Internet]. [cité 24 nov 2019]. Disponible sur: http://www.hivfrenchresistance.org/

39. Musoke PM, Mudiope P, Barlow-Mosha LN, Ajuna P, Bagenda D, Mubiru MM, et al. Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. BMC Pediatr. 2010;10(1):56.

40. Schoffelen AF, Wensing AMJ, Tempelman HA, Geelen SPM, Hoepelman AIM, Barth RE. Sustained Virological Response on Second-Line Antiretroviral Therapy following Virological Failure in HIV-Infected Patients in Rural South Africa. Sluis-Cremer N, éditeur. PLoS ONE. 2013;8(3):e58526.

41. Fielding KL, Charalambous S, Stenson AL, Pemba LF, Martin DJ, Wood R, et al. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis. 2008;8(1):93.

42. Ateba Ndongo F, Texier G, Ida Penda C, Tejiokem MC, Tetang Ndiang S, Ndongo J-A, et al. Virologic Response to Early Antiretroviral Therapy in HIV-infected Infants: Evaluation After 2 Years of Treatment in the Pediacam Study, Cameroon. Pediatr Infect Dis J. 2018;37(1):78.

43. Chiappini E, Galli L, Tovo P-A, Gabiano C, Lisi C, Bernardi S, et al. Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC Infect Dis. 2009;9(1):1.

44. Tassie J-M, Baijal P, Vitoria MA, Alisalad A, Crowley SP, Souteyrand Y. Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries. J Acquir Immune Defic Syndr. 1999;54(4):437–41.

45. Rouet F, Fassinou P, Inwoley A, Anaky M-F, Kouakoussui A, Rouzioux C, et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS Lond Engl. 2006;20(18):2315–9.

46. Tejiokem MC, Faye A, Penda IC, Guemkam G, Ateba Ndongo F, Chewa G, et al. Feasibility of Early Infant Diagnosis of HIV in Resource-Limited Settings: The ANRS 12140-PEDIACAM Study in Cameroon. Myer L, éditeur. PLoS ONE. 2011;6(7):e21840.

47. Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjananit S, Wannarit P, et al. Hospitalization and Mortality among HIV-Infected Children after Receiving Highly Active Antiretroviral Therapy. Clin Infect Dis. 2007;44(4):599–604.

48. van Dijk JH, Sutcliffe CG, Munsanje B, Sinywimaanzi P, Hamangaba F, Thuma PE, et al. HIV-infected children in rural Zambia achieve good immunologic and Virologic outcomes two years after initiating antiretroviral therapy. PLOS ONE. 2011;6(4):e19006.

49. Weigel R, Estill J, Egger M, Harries AD, Makombe S, Tweya H, et al. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS Lond Engl. 2012;26(3):365–73.

50. Polis MA, Sidorov IA, Yoder C, Jankelevich S, Metcalf J, Mueller BU, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet Lond Engl. 2001;358(9295):1760–5.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

* fast, convenient online submission

* thorough peer review by experienced researchers in your field

* rapid publication on acceptance

* support for research data, including large and complex data types

* gold Open Access which fosters wider collaboration and increased citations

* maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions